Brokerages Set Tempus AI, Inc. (NASDAQ:TEM) Price Target at $65.69

Shares of Tempus AI, Inc. (NASDAQ:TEM) have been given a consensus rating of “Hold” by the seventeen brokerages that are covering the company, Marketbeat.com reports. Two analysts have rated the stock with a sell recommendation, six have given a hold recommendation and nine have given a buy recommendation to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $65.6923.

A number of equities analysts recently issued reports on TEM shares. Stifel Nicolaus lowered their price target on Tempus AI from $60.00 to $50.00 and set a “hold” rating for the company in a report on Monday, August 3rd. Wall Street Zen raised shares of Tempus AI from a “sell” rating to a “hold” rating in a report on Saturday, July 25th. Needham & Company LLC restated a “buy” rating and set a $75.00 price objective on shares of Tempus AI in a research report on Friday, July 31st. Wolfe Research assumed coverage on shares of Tempus AI in a report on Tuesday, June 2nd. They issued a “peer perform” rating for the company. Finally, Weiss Ratings upgraded shares of Tempus AI from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, August 12th.

Insider Transactions at Tempus AI

In other Tempus AI news, CAO Ryan M. Bartolucci sold 6,175 shares of the firm’s stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $49.61, for a total transaction of $306,341.75. Following the transaction, the chief accounting officer owned 67,866 shares of the company’s stock, valued at approximately $3,366,832.26. This trade represents a 8.34% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Ryan Fukushima sold 14,286 shares of the firm’s stock in a transaction dated Friday, August 21st. The stock was sold at an average price of $70.00, for a total value of $1,000,020.00. Following the transaction, the chief executive officer directly owned 47,420 shares in the company, valued at approximately $3,319,400. The trade was a 23.15% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 791,238 shares of company stock valued at $39,653,732 over the last quarter. 24.26% of the stock is owned by corporate insiders.

Institutional Trading of Tempus AI

Large investors have recently made changes to their positions in the company. JPL Wealth Management LLC purchased a new stake in Tempus AI in the 3rd quarter valued at $26,000. Los Angeles Capital Management LLC purchased a new position in Tempus AI during the 4th quarter worth $27,000. EMC Capital Management purchased a new position in Tempus AI during the 2nd quarter worth $29,000. Harvest Fund Management Co. Ltd purchased a new position in Tempus AI during the 3rd quarter worth $38,000. Finally, Whittier Trust Co. increased its stake in Tempus AI by 190.0% in the first quarter. Whittier Trust Co. now owns 870 shares of the company’s stock valued at $41,000 after purchasing an additional 570 shares during the period. 24.22% of the stock is owned by institutional investors and hedge funds.

Tempus AI Stock Performance

NASDAQ:TEM opened at $68.73 on Friday. The firm has a market capitalization of $12.40 billion, a PE ratio of -47.73 and a beta of 3.58. The business’s fifty day moving average price is $53.57 and its 200 day moving average price is $51.49. The company has a debt-to-equity ratio of 3.06, a current ratio of 3.30 and a quick ratio of 3.16. Tempus AI has a 12 month low of $40.77 and a 12 month high of $104.32.

Tempus AI (NASDAQ:TEM) last announced its quarterly earnings results on Thursday, July 30th. The company reported ($0.04) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.10. Tempus AI had a negative return on equity of 50.28% and a negative net margin of 17.77%.The company had revenue of $382.49 million during the quarter, compared to the consensus estimate of $379.69 million. During the same period in the previous year, the business earned ($0.22) EPS. Tempus AI’s revenue for the quarter was up 21.6% on a year-over-year basis. On average, sell-side analysts anticipate that Tempus AI will post -1.38 earnings per share for the current fiscal year.

Tempus AI Company Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.